<DOC>
	<DOCNO>NCT00236028</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety infliximab ( Remicade ) patient early rheumatoid arthritis .</brief_summary>
	<brief_title>A Safety Efficacy Study Infliximab ( Remicade ) With Methotrexate Patients With Early Rheumatoid Arthritis</brief_title>
	<detailed_description>This randomize , multicenter , double-blind , active-treatment-controlled , three-arm , parallel study chronic treatment infliximab . This study determine whether infliximab , two different dos ( 3 mg/kg 6 mg/kg ) combination methotrexate ( MTX ) , reduce sign symptom ( joint pain , swell stiffness ) rheumatoid arthritis . The study also compare effect slow joint damage associate rheumatoid arthritis . Additional information safety infliximab treatment obtain . The study last 1 year . Patients receive methotrexate total eight intravenous infusion study medication ( Infliximab placebo ) space first year . After final infusion study medication , several follow-up visit make . Patients receive methotrexate ( start 7.5mg/wk , increase 20mg/wk week8 ) intravenous infusion study medication ( Infliximab 3 6mg/kg , placebo ) week 0 , 2 , 6 , every 8 week thereafter week 46 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis least 3 month less equal 3 year screen Active disease time screen preinfusion drug Pregnant , nursing , plan pregnancy within 18 month enrollment Incapacitated , largely wholly bedridden , confined wheelchair , little ability self care Rheumatic disease rheumatoid arthritis current systemic inflammatory condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Early Rheumatoid Arthritis</keyword>
</DOC>